Your browser doesn't support javascript.
An enhanced isothermal amplification assay for viral detection.
Qian, Jason; Boswell, Sarah A; Chidley, Christopher; Lu, Zhi-Xiang; Pettit, Mary E; Gaudio, Benjamin L; Fajnzylber, Jesse M; Ingram, Ryan T; Ward, Rebecca H; Li, Jonathan Z; Springer, Michael.
  • Qian J; Department of Systems Biology, Harvard Medical School, Boston, MA, 02115, USA.
  • Boswell SA; Laboratory of Systems Pharmacology, Harvard Medical School, Boston, MA, 02115, USA.
  • Chidley C; Biological and Biomedical Sciences Program, Harvard Medical School, Boston, MA, 02115, USA.
  • Lu ZX; Department of Systems Biology, Harvard Medical School, Boston, MA, 02115, USA.
  • Pettit ME; Laboratory of Systems Pharmacology, Harvard Medical School, Boston, MA, 02115, USA.
  • Gaudio BL; Laboratory of Systems Pharmacology, Harvard Medical School, Boston, MA, 02115, USA.
  • Fajnzylber JM; Department of Systems Biology, Harvard Medical School, Boston, MA, 02115, USA.
  • Ingram RT; Laboratory of Systems Pharmacology, Harvard Medical School, Boston, MA, 02115, USA.
  • Ward RH; Department of Systems Biology, Harvard Medical School, Boston, MA, 02115, USA.
  • Li JZ; Department of Systems Biology, Harvard Medical School, Boston, MA, 02115, USA.
  • Springer M; Laboratory of Systems Pharmacology, Harvard Medical School, Boston, MA, 02115, USA.
Nat Commun ; 11(1): 5920, 2020 11 20.
Article in English | MEDLINE | ID: covidwho-939437
ABSTRACT
Rapid, inexpensive, robust diagnostics are essential to control the spread of infectious diseases. Current state of the art diagnostics are highly sensitive and specific, but slow, and require expensive equipment. Here we report the development of a molecular diagnostic test for SARS-CoV-2 based on an enhanced recombinase polymerase amplification (eRPA) reaction. eRPA has a detection limit on patient samples down to 5 viral copies, requires minimal instrumentation, and is highly scalable and inexpensive. eRPA does not cross-react with other common coronaviruses, does not require RNA purification, and takes ~45 min from sample collection to results. eRPA represents a first step toward at-home SARS-CoV-2 detection and can be adapted to future viruses within days of genomic sequence availability.
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Nucleic Acid Amplification Techniques / Betacoronavirus Type of study: Diagnostic study / Prognostic study / Randomized controlled trials Limits: Humans Language: English Journal: Nat Commun Journal subject: Biology / Science Year: 2020 Document Type: Article Affiliation country: S41467-020-19258-y

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Nucleic Acid Amplification Techniques / Betacoronavirus Type of study: Diagnostic study / Prognostic study / Randomized controlled trials Limits: Humans Language: English Journal: Nat Commun Journal subject: Biology / Science Year: 2020 Document Type: Article Affiliation country: S41467-020-19258-y